Login to Your Account

Clinic Roundup

Thursday, January 31, 2013
• Alnylam Pharmaceuticals Inc., of Cambridge, Mass., and collaborators published results from a Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for treating solid tumors with liver involvement.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription